Vysis launches fluorescence in situ hybridisation (FISH) equipment:
This article was originally published in Clinica
Vysis has launched its HYBrite automated system for denaturation and hybridisation of in situ DNA probe procedures. The system reduces the time for fluorescence in situ hybridisation (FISH) procedures. The company has also launched its Quips genetic imaging software and Quips XL and LS genetic workstations for FISH procedures, comparative genomic hybridisation and karyotyping analyses. Quips software allows capture, enhancement, analysis and printing of high-quality images that identify genetic aberrations associated with pre- and postnatal diseases and cancer. The workstations use a fluorescence microscope to visualise and enhance fluorescent signals.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.